Format

Send to

Choose Destination
Future Oncol. 2016 Sep;12(18):2095-105. doi: 10.2217/fon-2016-0118. Epub 2016 May 18.

Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.

Author information

1
Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA.
2
Departments of Dermatology & Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

The Hedgehog inhibitors are promising alternative for patients with advanced basal cell carcinoma that are not amenable to radiotherapy or surgery. Sonidegib, also known as LDE225, is an orally available SMO antagonist that was recently approved by the US FDA for the treatment of patients with locally advanced basal cell carcinoma. This article will provide an overview of the pharmacology and pharmacokinetics of sonidegib and in-depth analysis of the BOLT trial with additional data from the 12-month update. The present challenges associated with Hedgehog inhibitors will also be discussed.

KEYWORDS:

BOLT trial; basal cell carcinoma; sonidegib

PMID:
27189494
DOI:
10.2217/fon-2016-0118
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center